Drug Profile
Pavurutamab - Amgen
Alternative Names: AMG 701 HLE-BiTE®; AMG-701Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 30 Jun 2023 Amgen completes a phase I/II trial for Multiple myeloma (Combination therapy, Monotherapy, Second line therapy or greater) in USA, the Netherlands, Australia, Belgium, Canada, Germany, Japan (IV) (NCT03287908) (EudraCT2017-001997-41) (JapicCTI205329)
- 04 Aug 2022 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Netherlands, Japan, Germany, Australia, Canada, USA, Belgium (IV)
- 04 Aug 2022 Discontinued - Phase-I for Multiple myeloma (Monotherapy, Second-line therapy or greater) in USA, Australia, Netherlands, Canada, Canada, Germany, Japan, Belgium (IV)